The drug is facing massive demand around the world, with its manufacturer Roche no longer able to supply New Zealand with the drug for the next three months. Pharmac has also announced today it will begin funding an alternative drug for people with severe rheumatoid arthritis who have been affected by the shortage.
This is a companion discussion topic for the original entry at https://www.sciencemediacentre.co.nz/2021/09/17/arthritis-drug-funded-to-treat-covid-19-expert-reaction/